Saturday 17 October 2026
Export YARW’s income statement to Excel — free account
Yarrow Bioscience, Inc
YARW Healthcare Biotechnology
Yarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 40.6%, EPS grew 67.1% and free cash flow grew 81.6%, each against the same quarter a year earlier.
18.78
1.22
−6.10%
Follow YARW
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
27.36 | 43.52 | 56.34 | 57.94 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.02) | (6.59) | (6.27) | (14.02) | |
P/B ratio |
0.45 | 0.89 | 1.04 | 1.27 | |
Price to Tangible BV |
0.51 | 1.05 | 1.24 | 1.55 | |
EV/Sales |
92.15 | 109.56 | 148.23 | 148.66 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.26) | (1.89) | (2.61) | (4.23) | |
EV/FCF |
(1.25) | (1.87) | (2.60) | (4.18) | |
Quick Ratio |
8.09 | 12.11 | 20.17 | 14.87 | |
Current Ratio |
8.87 | 12.53 | 20.86 | 15.26 | |
Net Debt/EBITDA |
4.12 | 5.47 | 6.51 | 7.40 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.97 | 0.78 | 1.14 | 0.66 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,110.06% | 2,289.23% | 950.00% | 812.37% | |
Selling, General and Administrative Expense of Revenue |
1,600.59% | 1,824.62% | 3,587.21% | 2,485.57% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
288.17% | 406.92% | 551.16% | 449.48% | |
Graham Net Nets |
2.22 | 1.11 | 0.96 | 0.79 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(232.84%) | (105.64%) | (82.40%) | (62.29%) | |
Free Cash Flow Yield |
(268.85%) | (134.29%) | (101.39%) | (61.30%) | |
Revenue per Share |
0.20 | 0.15 | 0.10 | 0.11 | |
Operating CF per Share |
(8.29) | (4.40) | (4.77) | (2.32) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(8.29) | (4.40) | (4.77) | (2.32) | |
Cash per Share |
38.20 | 33.91 | 29.14 | 26.72 | |
Shareholders Equity per Share |
37.49 | 32.46 | 28.80 | 25.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
37.49 | 32.46 | 28.80 | 25.71 | |
Free Cash Flow |
(7.10) | (3.76) | (4.08) | (1.99) | |
Working Capital |
31.84 | 27.62 | 24.55 | 21.98 | |
Net Current Asset Value |
31.84 | 27.62 | 24.55 | 21.98 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
2.59 | 1.87 | 1.90 | 1.01 | |
Average Assets |
56.17 | 48.53 | 41.15 | 34.16 | |
Average Common Equity |
47.81 | 39.93 | 34.38 | 30.47 |
Columns are period end dates